Meeting
2023 ASCO Annual Meeting
Expanded cohort and extended follow-up of neoadjuvant plus adjuvant (neo + adj) dabrafenib (D) and trametinib (T) in patients (pts) with surgically resectable stage (stg) III/IV melanoma.
Authors
Tarin Hennegan
MD Anderson Cancer Center, Houston, TX
Tarin Hennegan , Elizabeth M. Burton , Lauren Simpson , Victor Gerardo Prieto , Merrick I. Ross , Isabella Claudia Glitza , Lisa G Beal , Jeffrey E. Gershenwald , Hussein A. Tawbi , Michael K.K. Wong , Zhongya Wang , Roland L. Bassett Jr., Anthony Lucci , Jeffrey Edwin Lee , Sarah B. Fisher , Sapna Pradyuman Patel , Jennifer Leigh McQuade , Michael A. Davies , Jennifer Ann Wargo , Rodabe Navroze Amaria
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Local-Regional Disease
Clinical Trial Registration Number
NCT02231775
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9583)
DOI
10.1200/JCO.2023.41.16_suppl.9583
Abstract #
9583
Poster Bd #
346
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Relapse-free survial and target identification to enhance response with neoadjuvant and adjuvant dabrafenib + trametinib (D+T) treatment compared to standard-of-care (SOC) surgery in patients (pts) with high-risk resectable BRAF-mutant metastatic melanoma.
First Author: Jennifer Ann Wargo
Poster
2017 ASCO Annual Meeting
Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.
First Author: Zeynep Eroglu
Poster
2017 ASCO Annual Meeting
Preliminary results from the international neoadjuvant melanoma consortium (INMC).
First Author: Alexander M. Menzies
Poster
2015 ASCO Annual Meeting
Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.
First Author: Jennifer Ann Wargo